Analytical Data
-
Gene name
PD-1
- Application
-
Alternative Names
CD279; PDCD1; SLEB2; HPD1P
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15116
-
Expression Region
Leu41~Ala132
-
Molecular Weight
14kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that plays a crucial role in regulating the immune system and maintaining self-tolerance. Its interaction with programmed death-ligand 1 (PD-L1) and PD-L2 negatively regulates T-cell activation and promotes tumor immune evasion, making it a significant target in cancer immunotherapy. The study of PD-1 recombinant proteins has gained momentum due to their potential in developing therapeutic agents that can enhance anti-tumor immunity. PD-1 blockade has shown promising results in various cancers, leading to the approval of several monoclonal antibodies targeting PD-1 or PD-L1, such as pembrolizumab and nivolumab. Researchers are increasingly focusing on the structural and functional characterization of PD-1 to enhance our understanding of its mechanisms and to improve the efficacy and safety of PD-1-targeted therapies. Moreover, ongoing studies are investigating the combination of PD-1 inhibitors with other treatment modalities, including chemotherapy, targeted therapy, and radiation, to overcome resistance and increase response rates. The exploration of PD-1’s role in other diseases, such as autoimmune disorders and chronic infections, further highlights its relevance in both therapeutic and diagnostic applications, underlining the critical importance of PD-1 recombinant proteins in contemporary biomedical research.
